On Friday, HRG Group Inc (NYSE:HRG)’s shares declined -3.87% to $11.91.
HRG Group Inc (HRG) declared its merged results for the second quarter of Fiscal 2015 ended on March 31, 2015 (the “Fiscal 2015 Quarter”). The results comprise HRG’s four segments:
- Consumer Products, which comprises of Spectrum Brands Holdings, Inc. (“Spectrum Brands”; NYSE: SPB);
- Insurance, which comprises Fidelity & Guaranty Life (“FGL”; NYSE: FGL) and Front Street Re, Ltd. (“Front Street”);
- Energy, which comprises of Compass Production Partners, LP (“Compass”), a partner of HGI Energy Holdings, LLC (“HGI Energy”) engaged in the operation, acquisition and development of conventional oil and natural gas assets in the U.S.; and
- Asset Administration, which comprises Salus Capital Partners, LLC (“Salus”), Energy & Infrastructure Capital (“EIC”) and CorAmerica Capital, LLC (“CorAmerica”).
HRG Group, Inc., through its auxiliaries, provides various branded consumer products. The company operates in four segments: Consumer Products, Insurance, Energy, and Financial Services.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s shares dropped -3.57% to $5.68.
Spectrum Pharmaceuticals, Inc. (SPPI) declared financial results for the three-month period ended March 31, 2015.
Three-Month Period Ended March 31, 2015 (All numbers are approximate)
GAAP Results
Total product sales were $38.4 million (not taking into account $7 million in deferred revenue) in the first quarter of 2015. Total product sales reduced 4% from $40.1 million in the first quarter of 2014.
Product sales in the first quarter comprised of: FUSILEV® (levoleucovorin) net sales of $20.2 million, FOLOTYN® (pralatrexate injection) net sales of $9.3 million, ZEVALIN® (ibritumomab tiuxetan) net sales of $4.2 million, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $1.9 million and BELEODAQ® (belinostat) for Injection net sales of $2.8 million.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
At the end of Friday’s trade, Media General Inc (NYSE:MEG)‘s shares dipped -1.58% to $15.56.
Media General Inc (MEG) stated results for the first quarter that ended March 31, 2015.
Explanation of GAAP Results
The Company accomplished its merger with LIN Media on December 19, 2014. As a result, its first quarter 2014 GAAP financial results do not comprise LIN Media’s results, nor do they reflect the operating results of any attained stations for the period preceding to their acquisition, but do comprise the results of divested stations preceding to their divestiture.
Summary of Results for the First Quarter 2015 based on GAAP Financial Information
- Net revenues raised 106% to $297 million, contrast to $144 million in the preceding year.
- Digital revenues raised 514% to $30 million, contrast to the preceding year.
- Operating income was $21 million, contrast to $19 million in the preceding year.
- Adjusted EBITDA raised 87% to $72 million, contrast to Adjusted EBITDA of $38 million in the preceding year.
- The Company recognized pretax gains of $3.1 million for relocating stations to new spectrum in Lansing and Austin.
- Net loss per diluted share was $0.06, contrast to net earnings per diluted share of $0.06 in the preceding year.
Media General, Inc. owns and operates television stations in the United States. It operates 71 network-associated stations, and their associated digital media and mobile platforms, counting 22 CBS stations, 14 NBC stations, 12 ABC stations, 8 FOX stations, 7 MyNetworkTV stations, 7 CW stations, and 1 Telemundo station in 48 markets. Media General, Inc. was founded in 1850 and is headquartered in Richmond, Virginia.
Coty Inc (NYSE:COTY), ended its Friday’s trading session with -3.28% loss, and closed at $23.87.
Coty Inc (COTY) declared financial results for the third quarter of fiscal year 2015, ended March 31, 2015.
Third Quarter Fiscal 2015 Summary
- Net revenues of $933.8 million were flat like-for-like and reduced 7% as stated
- Adjusted operating income of $100.9 million raised 24% from $81.4 million in the preceding-year period
- Stated net income of $75.5 million raised from $(253.3) million in the preceding-year period reflecting a one-time asset impairment charge in the preceding-year period
- Adjusted net income of $63.6 million reduced from $86.7 million in the preceding-year period principally due to a favorable foreign tax settlement in the preceding-year period. Adjusted earnings per diluted share of $0.18 reduced from $0.22 in the preceding-year period
- Net cash offered by operating activities was $33.2 million contrast to $(4.2) million in the preceding-year period
Coty Inc., together with its auxiliaries, manufactures, markets, and distributes women’s and men’s fragrances, color cosmetics, and skin and body care related products worldwide. The company operates through three segments: Fragrances, Color Cosmetics, and Skin & Body Care.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
